Business Wire

William Shatner Launches Everbridge’s ‘Unlocking Resilience’ Global Leadership Podcast Series, Available Today

Share

Everbridge, Inc. (NASDAQ: EVBG) today announced the launch of its podcast Unlocking Resilience™: Global Leadership Seriesfeaturing William Shatner as its inaugural guest. The first-of-its-kind podcast features global influencers, government leaders, C-level executives and top healthcare experts as they discuss the confluence of leadership, technology and resilience at both the personal and organizational level. Topics will include overcoming personal challenges to create a life of resilience; effective strategies for building organizational resilience and business continuity in the face of critical events; and perspectives on the future of work, life and entertainment in a post-pandemic world, among other topics.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005565/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

William Shatner Launches Everbridge’s ‘Unlocking Resilience’ Global Leadership Podcast Series, Available Today (Graphic: Business Wire)

The Unlocking Resilience podcast, featuring William Shatner – available here – will also be downloadable from Apple Podcasts, Spotify, Google Podcasts, Pandora, iHeartRadio, Deezer, and JioSaavn & Gaana.

Epitomizing the essence of resilience, Shatner became the oldest person at age 90 to fly into space as part of an historic space launch last week aboard a Blue Origin sub-orbital capsule. Shatner articulated his ‘profound experience’ upon returning to earth. He cultivated a career spanning over 60 years as an award-winning actor, director, producer, writer, recording artist, and horseman. Shatner represents one of Hollywood’s most recognizable figures as well as serving as a major philanthropist.

In the first episode of Unlocking Resilience, Shatner shares, “It’s one thing to start your business, to start your day, and it’s going according to plan. But, the moment the phone doesn’t work, or the moment that someone comes in with a call, with an emergency… all of your plans are out the window. And now you need to be resilient. And it’s that resilience that makes the leader.”

Unlocking Resilience represents the latest extension of the successful Everbridge Global Leadership Series, which recently won a Gold Stevie® award for Communications Campaign of the Year, and featured over 100 speakers and attracted more than 40,000 business and government decision makers across 150 countries, to date. The new podcast serves an audience of C-level executives along with leaders at all levels across public and private organizations.

Hosts include Everbridge senior leaders Chief Executive Officer David Meredith; world-renowned technologist and Chief Experience Officer Dr. John Maeda; Chief Revenue Officer Vernon Irvin; Chief Digital Officer Suma Nallapati, and Chief Security Officer Tracy Reinhold. Upcoming guests and leaders in resilience will be announced over the remainder of the year.

“We developed the Everbridge ‘Unlocking Resilience’ podcast series to further share best practices, strategies and insights from many of the world’s top influencers, asking how they approach resilience in both their personal and professional lives,” said Everbridge’s David Meredith. “Our audience consists of C-level executives and decision makers from across industry and around the world, looking to challenge their own approach and practices to ensuring resilience.”

For every episode recorded, Everbridge will make a donation to The CDC Foundation, anonprofit authorized by the U.S. Congress to mobilize philanthropic partners and private-sector resources to support the Centers for Disease Control and Prevention (CDC’s) critical health protection mission.Since 1995, the CDC Foundation has raised over $1.6 billion and launched more than 1,200 programs impacting a variety of health threats from chronic disease conditions including cardiovascular disease and cancer, to infectious diseases like rotavirus and HIV, to emergency responses, including COVID-19 and Ebola. To contribute to the CDC Foundation, please visit the Everbridge Team giving page at https://give.cdcfoundation.org/Everbridge or the Crush COVID campaign at www.give4cdcf.org.

In his recent conversation with David Meredith, President Clinton shared perspective on bolstering nationwide preparation for, and response to, various digital, natural, and manmade crises, noting, “In the worst of times, we’re all just people, and our differences fade away, and we need the same things… [with] resilience, people are the architects of their future.”

During another keynote addressing businesses’ response to COVID-19, Steve Forbes said, “Companies have a new appreciation of preparedness [for large scale critical events], upping the game in terms of risk insurance. The very fact of how well so many businesses responded and did things, in a way that even they wouldn't have thought possible. I think this shows the spirit of innovation, creativity, versatility is very, very powerful.”

Everbridge’s Global Leadership Series featured discussions with Board and C-level business executives from Accenture, Aviva, Capital One, The Coca-Cola Company, Fannie Mae, Ford Motor Company, Fortinet, Goldman Sachs, Houston Methodist Hospital, Humana, IBM, Invesco, Major League Baseball, the Mayo Clinic, Moderna, Salesforce.com, Siemens, Volkswagen, and many others.

To listen to the Everbridge “Unlocking Resilience” podcast, visit the Everbridge Blog.

About Everbridge

Everbridge, Inc. (NASDAQ: EVBG) is a global software company that provides enterprise software applications that automate and accelerate organizations’ operational response to critical events in order to Keep People Safe and Organizations Running™. During public safety threats such as active shooter situations, terrorist attacks or severe weather conditions, as well as critical business events including IT outages, cyber-attacks or other incidents such as product recalls or supply-chain interruptions, over 5,800 global customers rely on the Company’s Critical Event Management Platform to quickly and reliably aggregate and assess threat data, locate people at risk and responders able to assist, automate the execution of pre-defined communications processes through the secure delivery to over 100 different communication modalities, and track progress on executing response plans. Everbridge serves 8 of the 10 largest U.S. cities, 9 of the 10 largest U.S.-based investment banks, 47 of the 50 busiest North American airports, 9 of the 10 largest global consulting firms, 8 of the 10 largest global automakers, 9 of the 10 largest U.S.-based health care providers, and 7 of the 10 largest technology companies in the world. Everbridge is based in Boston with additional offices in 25 cities around the globe. For more information visit www.everbridge.com

Cautionary Language Concerning Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the anticipated opportunity and trends for growth in our critical communications and enterprise safety applications and our overall business, our market opportunity, our expectations regarding sales of our products, our goal to maintain market leadership and extend the markets in which we compete for customers, and anticipated impact on financial results. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “expect,” “anticipate,” “should,” “believe,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,” variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the ability of our products and services to perform as intended and meet our customers’ expectations; our ability to successfully integrate businesses and assets that we may acquire; our ability to attract new customers and retain and increase sales to existing customers; our ability to increase sales of our Mass Notification application and/or ability to increase sales of our other applications; developments in the market for targeted and contextually relevant critical communications or the associated regulatory environment; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we have not been profitable on a consistent basis historically and may not achieve or maintain profitability in the future; the lengthy and unpredictable sales cycles for new customers; nature of our business exposes us to inherent liability risks; our ability to attract, integrate and retain qualified personnel; our ability to maintain successful relationships with our channel partners and technology partners; our ability to manage our growth effectively; our ability to respond to competitive pressures; potential liability related to privacy and security of personally identifiable information; our ability to protect our intellectual property rights, and the other risks detailed in our risk factors discussed in filings with the U.S. Securities and Exchange Commission (“SEC”), including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on February 26, 2021. The forward-looking statements included in this press release represent our views as of the date of this press release. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

All Everbridge products are trademarks of Everbridge, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Everbridge Media Relations Contacts:

Jeff Young
jeff.young@everbridge.com
781-859-4116

Kevin Carter
kevin.carter@everbridge.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye